-
Study aim
-
To investigate the results of ICSI in divided doses of GNRH agonist as a trigger for hyperresponders.
-
Design
-
Randomized cotrolled trial with panrallel groups, single blind on 122 samples. Sealedenvelope.com was used for randomization.
-
Settings and conduct
-
Patients referring to Avicenna Infertility Center will be treated for infertility through ICSI in two treatment groups with two different drug regimens, and the results will be compared with each other. Outcome assessors are blinded to the intervention.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria include: age 18 to 39 years, according to the definition of excessive respondents (more equal to 17 follicles above equal to 11 mm per trigger day), body mass index 18-30 kg/m2, presence of both ovaries, Indications for intracytoplasmic sperm injection, stimulation in a gonadotropin-releasing hormone (GnRHa) protocol
Exclusion criteria include: human chorionic gonadotropin (hCG) stimulated cycles, donor cycles, severe male factor with sperm count below two million, patients with hypogonadotrophic hypogonadism and uterine abnormalities, unwillingness to participate in the study.
-
Intervention groups
-
Group A: 0.3 mg of gonadotropin-releasing hormone agonist 36 hours before ovulation and LH is measured on the third day of the cycle and 12 hours after trigger injection and on the day of ovarian puncture.
Group B: 0.2 mg of agonist 36 hours before ovulation plus a repeat dose of 0.1 mg of agonist 24 hours after the first dose is administered to approach the body's physiological surge pattern.
-
Main outcome variables
-
The number of germinal vesicle (GV) oocytes and metaphase one and two metaphase oocytes, fertilization rate, clinical pregnancy rate, number of quality embryos, ovarian hyperstimulation syndrome rate and empty follicle syndrome rate.